The top most asked questions about Ozempic

14 May 2024

A new study by diabetes awareness website Diabetes Strong reveals that “How to get Ozempic” is the most googled question about the medication.

The study analyzed through Ahrefs the most common questions people have googled, sorting them by category and aggregating the average search volume by topic to discover which “Ozempic” related query is the most popular.

Ozempic (semaglutide) is Danish drugmaker Novo Nordisk’s (NOV: N) top selling diabetes treatment but it is also approved and marketed under the Wegovy name for the treatment of obesity. Both products have been in short supply because of their use by celebrities and influences for weight management.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK